Showing results (71-80 of 94) with videos related to

Sort By:
Pageof 10
Nature Communications|June 5, 2019
Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutationsRichard W Birkinshaw, Jia-Nan Gong, Cindy S Luo, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 24, 2026
Persistent and pathogen-specific infection risk during long-term survivorship after CD19 CAR-T: An Australian multi-centre cohort studyGemma K Reynolds, Mark R Dowling, Safia Belbachir, et al.
Blood|June 11, 2021
Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapyShuo Ma, John F Seymour, Danielle M Brander, et al.
The New England Journal of Medicine|March 29, 2018
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell LymphomaConstantine S Tam, Mary Ann Anderson, Christiane Pott, et al.
Blood Advances|December 11, 2025
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphomaSasanka M Handunnetti, Amit Khot, Piers Blombery, et al.
Blood|October 26, 2023
CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC studyAdrian Minson, Nada Hamad, Chan Y Cheah, et al.
Blood|April 13, 2016
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanismMary Ann Anderson, Jing Deng, John F Seymour, et al.
Blood|September 1, 2021
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLLPiers Blombery, Thomas E Lew, Michael A Dengler, et al.
Blood Advances|December 15, 2022
Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cellsCharis E Teh, Hongke Peng, Meng-Xiao Luo, et al.
Blood Advances|August 19, 2025
Zanubrutinib in the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studiesConstantine S Tam, Mary Ann Anderson, Martin Simkovic, et al.
Pageof 10